All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

SOHO 2019 | What is in the pipeline for the treatment of T-cell lymphoma?

Featured:

Owen O'ConnorOwen O'Connor

Sep 18, 2019


During SOHO 2019, Houston, US, the Lymphoma Hub asked Dr Owen A. O’Connor from Columbia University, New York, US, about treatments in the pipeline for T-cell lymphoma. He gives an update on the recent clinical developments for patients with relapsed or refractory diseases. He also describes treatment paradigms incorporating combinations of drugs with novel backbones, which hopefully in the future will replace CHOP-based therapies.

What is in the pipeline for the treatment of T-cell lymphoma?

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?